|
OALib Journal期刊
ISSN: 2333-9721
费用：99美元
|
|
|
|
共无定形药物——新型单相无定形二元体系
DOI: 10.7536/PC130755, PP. 478-486
Keywords: 共无定形,单相二元体系,形成机理,玻璃化转变温度,稳定性
Abstract:
共无定形药物是活性药物成分与其他小分子固体物质（药物或辅料）结合形成的具有单一玻璃化转变温度的单相无定形二元体系。它作为一种新的药物固体形态，可能改善药物的溶解度、溶出速率、稳定性及生物利用度等理化性质，已成为药物研发的一种新途径。本文主要对共无定形药物的定义、形成机理、制备方法、分析鉴别方法、物理化学稳定性以及溶解度和溶出速率进行综述，并对共无定形与固体分散体和共晶的比较进行了概述。
| [1] | Radtke M. New Drugs, 2001, 3: 62.
|
| [2] | Hu J, Johnston K P, Williams R O. Int. J. Pharm., 2004, 271: 145.
|
| [3] | 马坤(Ma K), 高静(Gao J), 马磊(Ma L). 中国药科大学学报(Journal of China Pharmaceutical University), 2012, 43(5): 475.
|
| [4] | 高缘(Gao Y), 祖卉(Zu H), 张建军(Zhang J J). 化学进展(Progress in Chemistry), 2010, 22(5): 829.
|
| [5] | Lu Q, Zografi G. Pharm. Res., 1998, 15: 1202.
|
| [6] | L？bmann K, Laitinen R, Grohganz H, Gordon K C, Strachan C, Rades T. Mol. Pharm., 2011, 8: 1919.
|
| [7] | Hoppu P, Jouppila K, Rantanen J, Schantz S, Juppo A M. J. Pharm. Pharmacol., 2007, 59: 373.
|
| [8] | Schilling S U, Bruce C D, Shah N H, Malick A W, McGinity J W. Int. J. Pharm., 2008, 361: 158.
|
| [9] | Masuda T, Yoshihashi Y, Yonemochi E, Fujii K, Uekusa H, Terada K. Int. J. Pharm., 2012, 422: 160.
|
| [10] | Gao Y, Liao J, Qi X, Zhang J. Int. J. Pharm., 2013, 450: 290.
|
| [11] | Alles M, Chieng N, Rehder S, Rantanen J, Rades T, Aaltonen J. J. Control. Release, 2009, 136: 45.
|
| [12] | L？bmann K, Strachan C, Grohganz H, Rades T, Korhonen O, Laitinen R. Eur. J. Pharm. Biopharm., 2012, 81: 159.
|
| [13] | Vasconcelos T, Sarmento B, Costa P. Drug Discov. Today, 2007, 12: 1068.
|
| [14] | Janssens S, Mooter G V. J. Pharm. Pharmacol., 2009, 61: 1571.
|
| [15] | Qian F, Huang J, Hussain M A. J. Pharm. Sci., 2010, 99: 2941.
|
| [16] | L？bmann K, Laitinen R, Grohganz H, Strachan C, Rades T, Gordon K C. Int. J. Pharm., 2013, 453: 80.
|
| [17] | Yamamura S, Gotoh H, Sakamoto Y, Momose Y. Eur. J. Pharm. Biopharm., 2000, 49: 259.
|
| [18] | Dudognon E, Willart J F, Caron V, Capet F, Larsson T, Descamps M. Solid State Commun., 2006, 138: 68.
|
| [19] | Chieng N, Aaltonen J, Saville D, Rades T. Eur. J. Pharm. Biopharm., 2009, 71: 47.
|
| [20] | Forster A, Hempenstall J, Tucker, Rades T. Drug Dev. Ind. Pharm., 2001, 27: 549.
|
| [21] | Schneider H A. Macromol. Chem. Phys., 1988, 189: 1941.
|
| [22] | Nair R, Nyamweya N, G？nen S, Martínez-Miranda L J, Hoag S W. Int. J. Pharm., 2001, 225: 83.
|
| [23] | Gupta P, Thilagavathi R, Chakraborti A K, Bansal A K. Mol. Pharm., 2005, 2: 384.
|
| [24] | Shamblin S L, Huang E Y, Zografi G. J. Therm. Anal. Calorim., 1996, 47: 1567.
|
| [25] | Taylor L S, Zografi G. J. Pharm. Sci., 1998, 87: 1615.
|
| [26] | Lara-ochoa F, Espinosa-pérez G. Supramol. Chem., 2007, 19: 553.
|
| [27] | Morissette S L, Almarsson O, Peterson M L, Remenar J F, Read M J, Lemmo A V, Ellis S, Cima M J, Gardner C R. Adv. Drug Deliver. Rev., 2004, 56: 275.
|
| [28] | Descamps M, Willart J F, Dudognon E, Caron V. Journal of Pharmaceutical Science, 2007, 96: 1398.
|
| [29] | Ahuja N, Katare O P, Singh B. Eur. J. Pharm. Biopharm., 2007, 65: 26.
|
| [30] | L？bnmann K, Grohganz H, Laitinen R, Strachan C, Rades T. Eur. J. Pharm. Biopharm., 2013, 85: 873.
|
| [31] | Leuner C, Dressman J. Eur. J. Pharm. Biopharm., 2000, 50: 47.
|
| [32] | Serajuddin A T M. J. Pharm. Sci., 1999, 88: 1058.
|
| [33] | Zheng W, Jain A, Papoutsakis D, Dannenfelser R M, Panicucci R, Garad S. Drug Dev. Ind. Pharm., 2012, 38: 235.
|
| [34] | Yamamura S, Gotoh H, Sakamoto Y, Momose Y. Int. J. Pharm., 2002, 241: 213.
|
| [35] | Duer M J. Solid-State NMR Spectroscopy Principles and Applications. Blackwell Science, 2002. 391.
|
| [36] | Schantz S, Hoppu P, Juppo A M. J. Pharm. Sci., 2009, 98: 1862.
|
| [37] | Yu L. Adv. Drug Deliver. Rev., 2001, 48: 27.
|
Full-Text
|
|
Contact Us
service@oalib.com QQ:3279437679 
WhatsApp +8615387084133
|
|
